advances-in-protein-chemistry

More documents

Recommendations

Info

26. Walczak RJ, Dickens ML, Priestley ND, Strohl WR (1999) Purification, properties, and characterization of recombinant Streptomyces sp. strain C5 DoxA, a cytochrome P-450 catalyzing multiple steps in doxorubicin biosynthesis. J Bacteriol 181: 298-304. 27. Encyclopedia of immunology (1998) P J Delves (eds.). (2ndedn), Science direct, Amsterdam, Netherlands. 28. Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345: 340-350. 29. Stüve O, Youssef S, Weber MS, Nessler S, von Büdingen HC, et al. (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116: 1037-1044. 30. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, et al. (2004) Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 114: 582-588. 31. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932–1939. 32. Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397-440. 33. O’Shea JJ, Ma A, Lipsky P (2002) Cytokines and autoimmunity. Nat Rev Immunol 2: 37-45. 34. Sharpe AH, Abbas AK (2006) T-cell costimulation--biology, therapeutic potential, and challenges. N Engl J Med 355: 973-975. 35. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum., 54: 2793-2806. 36. Chaplin DD (2006) 1. Overview of the human immune response. J Allergy Clin Immunol 117: 430-435. 37. Lin J, Sampson HA (2009) The role of immunoglobulin E-binding epitopes in the characterization of food allergy. Curr Opin Allergy Clin Immunol 9: 357-363. 38. Savage JH, Matsui EC, Skripak JM, Wood RA (2007) The natural history of egg allergy. J Allergy Clin Immunol 120: 1413-1417. 39. Sicherer SH, Muñoz-Furlong A, Godbold JH, Sampson HA (2010) US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year followup. J Allergy Clin Immunol 125: 1322-1326. 40. Patriarca G, Nucera E, Roncallo C, Pollastrini E, Bartolozzi F, et al. (2003) Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther 17: 459-465. 41. Husby S (2000) Normal immune responses to ingested foods. J Pediatr Gastroenterol Nutr 30: 13-19. 42. Li XM, Srivastava K, Grishin A, Huang CK, Schofield B, et al. (2003) Persistent protective effect of heat-killed Escherichia coli producing “engineered,” recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol 112: 159-167. 43. Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, et al. (1999) Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 341: 1966-1973. 44. Stöger E, Vaquero C, Torres E, Sack M, Nicholson L, et al. (2000) Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Mol Biol 42: 583-590. 45. Fischer R, Emans N (2000) Molecular farming of pharmaceutical proteins. Transgenic Res 9: 279-299. 46. Giddings G (2001) Transgenic plants as protein factories. Curr Opin Biotechnol 12: 450-454. 47. Andersen DC, Krummen L (2002) Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol 13: 117-123. 48. Marx V (2005) Watching peptide drugs grow up. Chem. Eng. News 83: 17–24. 49. Sato AK, Viswanathan M, Kent RB, Wood CR (2006) Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 17: 638-642. 50. Sato AK, Viswanathan M, Kent RB, Wood CR (2006) Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 17: 638-642. 51. Woodley JF (1994) Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst 11: 61-95. 52. Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP (2001) Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 22: 2329-2343. 53. Bray BL (2003) Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov 2: 587-593. 54. Angelini A, Cendron L, Chen S, Touati J, Winter G, et al. (2012) Bicyclic peptide inhibitor reveals large contact interface with a protease target. ACS Chem Biol 7: 817-821. OMICS Group eBooks 015
Advances in Protein Chemistry Chapter: New Protein Purification Approaches Edited by: Ghulam Md Ashraf and Ishfaq Ahmed Sheikh Published by OMICS Group eBooks 731 Gull Ave, Foster City. CA 94404, USA Copyright © 2013 OMICS Group All book chapters are Open Access distributed under the Creative Commons Attribution 3.0 license, which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. However, users who aim to disseminate and distribute copies of this book as a whole must not seek monetary compensation for such service (excluded OMICS Group representatives and agreed collaborations). After this work has been published by OMICS Group, authors have the right to republish it, in whole or part, in any publication of which they are the author, and to make other personal use of the work. Any republication, referencing or personal use of the work must explicitly identify the original source. Notice: Statements and opinions expressed in the book are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book. Cover OMICS Group Design team First published November, 2013 A free online edition of this book is available at www.esciencecentral.org/ebooks Additional hard copies can be obtained from orders @ www.esciencecentral.org/ebooks
Page 1 and 2:
www.esciencecentral.org/ebooks Adva
Page 3 and 4:
Tyrosine Nitrated Proteins: Biochem
Page 5 and 6:
[58-61]. Protein sulfhydryls [62] a
Page 7 and 8:
2. Souza JM, Daikhin E, Yudkoff M,
Page 9 and 10:
Oligoclonality of the antibody resp
Page 11 and 12:
The Recent Methodologies of Protein
Page 13 and 14:
are due to altering protein activit
Page 15 and 16:
Figure 6: At Domain Level, Protein
Page 17 and 18:
Brownian Dynamics (BD) method Prote
Page 19 and 20: protein demonstrate the lowest ener
Page 21 and 22: Figure 12: Steps in Protein Prepara
Page 23 and 24: FlexServ The flexibility of protein
Page 25 and 26: 21. van der Kamp MW, Shaw KE, Woods
Page 27 and 28: Advances in Protein Thermodynamics
Page 29 and 30: 3. Fluorescence correlation spectro
Page 31 and 32: Figure 3: Molecular Chaperone (Top
Page 33 and 34: Figure 7: A Potherse is Consists of
Page 35 and 36: Figure 12: Residue Clusters with Mu
Page 37 and 38: Figure 16: Various Features at the
Page 39 and 40: Figure 21: Stability of protein str
Page 41 and 42: Advances in Protein Chemistry Chapt
Page 43 and 44: MMPs are believed to remodel the EC
Page 45 and 46: MMPs7 (Matrilysin, PUMP 1) A big ro
Page 47 and 48: MMP27 (MMP-22, C-MMP) mRNAs for MMP
Page 49 and 50: Signal transduction MMP production
Page 51 and 52: a | Active MMPs are generated throu
Page 53 and 54: Future Perspective Research into ne
Page 55 and 56: 56. Yonemura Y, Endo Y, Fujita H, K
Page 57 and 58: 126. López-Boado YS, Wilson CL, Ho
Page 59 and 60: Proteins and Peptides- Reemergence
Page 61 and 62: Figure 3: Schematic representation
Page 63 and 64: Figure 6: Different mechanisms of c
Page 65 and 66: [30,33]. Clinical trials with autoi
Page 67 and 68: Therapeutic Proteins Figure 9: Mole
Page 69: Coming years will witness increasin
Page 73 and 74: purification methodology and laid t
Page 75 and 76: An overview of various purification
Page 77 and 78: Affinity chromatography (AC): The p
Page 79 and 80: molecules such as proteins. Further
Page 81 and 82: However, for proteins with poor sol
Page 83 and 84: The schematic of an HPLC instrument
Page 85 and 86: » Denaturation of all proteins giv
Page 89 and 90: the biological society access to th
Page 91 and 92: identifier, since a single macromol
Page 93 and 94: Furthermore, the initial models for
Page 95 and 96: evaluation [78], Whatcheck [79] and
Page 97 and 98: corresponding to gaps in the FR ali
Page 99 and 100: programming (IP) problem based on t
Page 101 and 102: or almost the entire target. - Temp
Page 103 and 104: 3.2.1.10 Geno3D http://geno3d-pbil.
Page 105 and 106: 80. Laskowski RA, MacArthur MW, Mos
Page 107 and 108: 165. Zhang Y, Kolinski A, Skolnick
Page 111 and 112: Figure 1: Biochemical and biophysic
Page 113 and 114: equilibrium an equilibrium concentr
Page 115 and 116: for virtually all macromolecules to
Page 117 and 118: egion) for estimating fraction or p
Page 119 and 120: etween proteins in living cells. It
Page 121 and 122:
pre-requisite in understanding how
Page 123 and 124:
82. Rodger A, Marrington R, Roper D
Page 125 and 126:
New Peptide Based Therapeutic Appro
Page 127 and 128:
ability to selectively target cells
Page 129 and 130:
24 amino acid extracellular domain
Page 131 and 132:
separation efficiency. However, use
Page 133 and 134:
the peptides through acetylation an
Page 135 and 136:
63. Mesiano AJ, Beckman EJ, Russell
Page 137 and 138:
Antimicrob Agents Chemother 49: 330
Page 139 and 140:
Protein Detection Techniques Dennis
Page 141 and 142:
technique has been applied to the i
Page 143 and 144:
involves placing our protein of int
show all

advances-in-protein-chemistry

Create successful ePaper yourself

Delete template?

Save as template?